Imunon (IMNN) EBITDA Margin (2017 - 2022)
Imunon's (IMNN) quarterly EBITDA Margin came in at 5541.4% in Q4 2022, down 1819446.0% YoY from N/an in Q4 2021, and down 12.18% on a QoQ basis from 4939.65% in Q3 2022.
Imunon (IMNN) EBITDA Margin (2017 - 2022) Analysis & Trends
Imunon (IMNN) has 6 years of EBITDA Margin data on file, last reported at 5541.4% in Q4 2022.
- Quarterly EBITDA Margin fell 1819446.0% year-over-year to 5541.4% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 4984.31% (down 504431.0% YoY) and the FY2022 annual result came in at 4984.31%, down 504431.0% from the prior year.
- EBITDA Margin declined to 5541.4% in Q4 2022, from 4939.65% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 23451.74% in Q4 2018 to a low of 6409.08% in Q2 2018.
- A 5-year average of 716.32% and a median of 3968.84% in 2021 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2018 — EBITDA Margin jumped 2719670 bps — and 2020, when it sank 2624933 bps.
- Tracing IMNN's EBITDA Margin over 5 years: stood at 23451.74% in 2018, then decreased by 4 bps to 22414.25% in 2019, then tumbled by 117 bps to 3835.09% in 2020, then jumped by 430 bps to 12653.06% in 2021, then sank by 144 bps to 5541.4% in 2022.
- The last three EBITDA Margin figures came in at 5541.4% (Q4 2022), 4939.65% (Q3 2022), and 4782.62% (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 19.75% |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -5,541.40% |
| Sep 30, 2022 | -4,939.65% |
| Jun 30, 2022 | -4,782.62% |
| Mar 31, 2022 | -4,673.58% |
| Dec 31, 2021 | 12,653.06% |
| Sep 30, 2021 | -4,049.26% |
| Jun 30, 2021 | -4,057.12% |
| Mar 31, 2021 | -4,306.68% |
| Dec 31, 2020 | -3,835.09% |
| Sep 30, 2020 | -3,327.68% |
| Jun 30, 2020 | -3,813.60% |
| Mar 31, 2020 | -3,812.76% |
| Dec 31, 2019 | 22,414.25% |
| Sep 30, 2019 | -4,310.02% |
| Jun 30, 2019 | -4,455.81% |
| Mar 31, 2019 | -3,888.42% |
| Dec 31, 2018 | 23,451.74% |
| Sep 30, 2018 | -3,217.78% |
| Jun 30, 2018 | -6,409.08% |
| Mar 31, 2018 | -3,424.88% |